预约演示
更新于：2026-06-10
Etrasimod Arginine
精氨酸艾曲莫德
更新于：2026-06-10
概要
基本信息
药物类型 小分子化药 |
别名 Etrasimod arginine、Etrasimod L-arginine、伊曲莫德 + [10] |
作用方式 激动剂 |
作用机制 EDG6激动剂(鞘氨醇-1-磷酸受体-Edg-6激动剂)、S1PR1激动剂(鞘氨醇-1-磷酸受体-Edg-1激动剂)、S1PR5激动剂(鞘氨醇-1-磷酸受体-Edg-8激动剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2023-10-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H40F3N5O5 |
InChIKeyGVPVVOSNDUAUKM-BPGOJFKZSA-N |
CAS号1206123-97-8 |
关联
36
项与 精氨酸艾曲莫德 相关的临床试验NCT07470879
A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
NCT07459686
Velsipity® Tablets 2 mg Special Investigation (Investigation on Long-Term Use in Patients With Ulcerative Colitis)
NCT07486921
Etrasimod as Primary and Secondary Prevention of Pouchitis (ESPIRIT)
100 项与 精氨酸艾曲莫德 相关的临床结果
登录后查看更多信息
100 项与 精氨酸艾曲莫德 相关的转化医学
登录后查看更多信息
100 项与 精氨酸艾曲莫德 相关的专利（医药）
登录后查看更多信息
135
项与 精氨酸艾曲莫德 相关的文献（医药）2026-06-01BIOMEDICINE & PHARMACOTHERAPY
Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds
Review
作者: Gisbert, Javier P ; Bernardo, David ; De Prado, Ángel ; García-Alonso, F Javier ; Barrio, Jesús ; Arribas-Rodríguez, Elisa
While cytokine-targeted therapies have significantly transformed the treatment landscape of inflammatory bowel disease (IBD), a substantial proportion of patients remain refractory or lose responsiveness over time. Moreover, cytokine blockade alone may be insufficient to control the highly complex and heterogeneous immune dysregulation that characterizes intestinal inflammation. This has prompted the development of alternative biologic and small-molecule therapies targeting non-cytokine pathways implicated in intestinal inflammation, acting at distinct regulatory levels including immune cell trafficking, intracellular signalling, and lymphocyte recirculation. Here, we review emerging and approved non-cytokine-targeted therapies in IBD, focusing on three major mechanistic categories: anti-integrin agents (vedolizumab, natalizumab, etrolizumab) that selectively block leukocyte trafficking to the intestinal mucosa; Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway inhibitors (tofacitinib, upadacitinib, filgotinib) that interrupt multiple cytokine-mediated intracellular signalling cascades; and sphingosine-1-phosphate (S1P) receptor modulators (ozanimod, etrasimod) that sequester lymphocytes within lymphoid organs by functionally antagonizing S1P1 receptors. For each therapeutic class, we summarize the mechanistic rationale, clinical efficacy, safety profiles, and positioning within current treatment algorithms. Non-cytokine-based therapies represent a critical advance in the personalized management of IBD. By targeting complementary immunological mechanisms beyond cytokine inhibition, they offer new therapeutic options for patients with treatment-refractory disease and expand the arsenal for combination strategies. Furthermore, they highlight the need for precision medicine approaches guided by immune phenotyping, pharmacokinetic monitoring, and biomarker development to optimize therapeutic selection and improve long-term outcomes.
2026-05-08Journal of Crohns & Colitis
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus
Article
作者: Dulai, Parambir ; Jairath, Vipul ; Turner, Dan ; Danese, Silvio ; Long, Millie ; Dotan, Iris ; Sands, Bruce E ; Magro, Fernando ; Hart, Ailsa ; Armuzzi, Alessandro ; Ma, Christopher ; Verstockt, Bram ; Reinisch, Walter ; Dignass, Axel ; Peyrin-Biroulet, Laurent ; Wils, Pauline ; Rubin, David T ; Gearry, Richard ; Vieujean, Sophie ; Kobayashi, Taku
Abstract:
Background & Aims:
Prolonged washout periods between advanced therapies and investigational drugs are commonly required in inflammatory bowel disease (IBD) randomized controlled trials (RCTs). These requirements restrict patient enrollment and diverge from real-world clinical practice. This study aimed to establish an international expert consensus on washout durations for advanced therapies and conventional immunosuppressants (IS) in IBD clinical trials and to propose methodological recommendations for future study designs.
Methods:
An international panel of 12 IBD clinical trial experts participated in a Delphi consensus process. Agreement of ≥75% among participants was predefined as consensus.
Results:
A total of 12 statements were approved. Consensus was reached to eliminate washout periods for conventional IS (thiopurines, tacrolimus, methotrexate, and mycophenolate mofetil). For golimumab and ozanimod, experts agreed on a 2-week washout period. For other biologics (infliximab, adalimumab, vedolizumab, ustekinumab, and anti–IL-23 agents), most participants favored a 2–4-week washout duration and for JAK inhibitors and etrasimod, participants supported a short 2-week washout, though without reaching formal consensus. Experts recommended incorporating washout-based stratification (<4 vs ≥4 weeks) at randomization into future trial designs to evaluate its impact on safety, pharmacokinetics, and efficacy outcomes.
Conclusions:
This international Delphi consensus highlights the need to adapt current washout practices in IBD RCTs to real-world practice. Experts supported shorter and standardized washout durations—preferably less than 4 weeks—to better align with clinical practice, while maintaining patient safety. Acceptance of these recommendations by regulators could harmonize washout duration criteria, enhance recruitment efficiency, and accelerate patient access to innovative therapies without compromising safety.
2026-05-01Gastroenterologia y Hepatologia
Review
作者: Gutiérrez Casbas, Ana ; Cábez, Ana ; Zabana, Yamile
Modulation of sphingosine-1-phosphate receptors represents a relatively recent approach in the treatment of inflammatory bowel disease, although these modulators have been approved since 2010 for other inflammatory conditions such as multiple sclerosis. Etrasimod is a sphingosine-1-phosphate receptor (S1PR) modulator that binds to S1PR1, S1PR4 and S1PR5 receptors, and its efficacy has been demonstrated in the treatment of moderately to severely active ulcerative colitis. It is a small molecule and synthetic drug administered orally, with a proper bioavailability and a fast elimination rate, predictable pharmacokinetics and lack of immunogenicity, which are convenient characteristics for both efficacy and safety. This article reviews the pharmacological characteristics of etrasimod and its safety profile.
100 项与 精氨酸艾曲莫德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 欧盟 | 2024-02-16 | |
| 活动性中度溃疡性结肠炎 | 冰岛 | 2024-02-16 | |
| 活动性中度溃疡性结肠炎 | 列支敦士登 | 2024-02-16 | |
| 活动性中度溃疡性结肠炎 | 挪威 | 2024-02-16 | |
| 活动性重度溃疡性结肠炎 | 欧盟 | 2024-02-16 | |
| 活动性重度溃疡性结肠炎 | 冰岛 | 2024-02-16 | |
| 活动性重度溃疡性结肠炎 | 列支敦士登 | 2024-02-16 | |
| 活动性重度溃疡性结肠炎 | 挪威 | 2024-02-16 | |
| 溃疡性结肠炎 | 美国 | 2023-10-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 湿疹 | 临床3期 | 美国 | 2023-01-18 | |
| 湿疹 | 临床3期 | 加拿大 | 2023-01-18 | |
| 湿疹 | 临床3期 | 捷克 | 2023-01-18 | |
| 湿疹 | 临床3期 | 波兰 | 2023-01-18 | |
| 中度特应性皮炎 | 临床3期 | 美国 | 2023-01-18 | |
| 中度特应性皮炎 | 临床3期 | 加拿大 | 2023-01-18 | |
| 中度特应性皮炎 | 临床3期 | 捷克 | 2023-01-18 | |
| 中度特应性皮炎 | 临床3期 | 波兰 | 2023-01-18 | |
| 重度特应性皮炎 | 临床3期 | 美国 | 2023-01-18 | |
| 重度特应性皮炎 | 临床3期 | 加拿大 | 2023-01-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | Etrasimod 1 mg QD | 衊齋遞艱簾餘襯選廠鏇(糧築齋選築鏇獵簾膚鑰) = 襯觸壓夢襯糧鹹鹽淵網 構網築獵襯夢衊鑰壓窪 (淵餘廠鹽簾餘襯網範簾 ) 更多 | 积极 | 2026-04-30 | ||
Etrasimod 2 mg QD | 衊齋遞艱簾餘襯選廠鏇(糧築齋選築鏇獵簾膚鑰) = 遞憲鏇餘淵廠獵膚顧獵 構網築獵襯夢衊鑰壓窪 (淵餘廠鹽簾餘襯網範簾 ) 更多 | ||||||
N/A | 20 | 網鹽積鏇餘糧選憲憲襯(艱廠願醖鹹顧鏇廠襯艱) = 鑰膚構衊築願築艱夢網 鬱獵襯築鏇鹹齋顧艱遞 (構積繭憲鬱齋選淵艱築 ) 更多 | 积极 | 2026-02-18 | |||
临床3期 | 214 | Etrasimod 2 mg QD | 窪醖網衊築衊憲衊衊齋(鑰繭蓋構鬱鏇獵衊鬱鏇) = 襯範壓餘獵繭夢衊製製 簾鏇鹽衊範願憲範構遞 (繭廠鹹簾鹹鑰齋鏇齋鬱 ) 更多 | 积极 | 2026-02-18 | ||
临床3期 | 340 | 願衊願淵鹽壓壓廠壓繭(餘鏇蓋齋糧襯齋齋壓膚) = 繭構鏇淵獵顧壓願憲窪 鬱鬱獵鹽鬱夢積鏇製壓 (窪築醖鹹蓋鏇願醖構網 ) 更多 | 积极 | 2026-02-18 | |||
Placebo | 願衊願淵鹽壓壓廠壓繭(餘鏇蓋齋糧襯齋齋壓膚) = 廠齋艱鹹淵積製窪襯選 鬱鬱獵鹽鬱夢積鏇製壓 (窪築醖鹹蓋鏇願醖構網 ) 更多 | ||||||
N/A | 39 | 糧顧醖憲餘築夢遞蓋鹹(觸繭糧膚鬱網壓餘鹽夢) = 衊鑰鹹醖範齋膚壓襯憲 鹹鏇鏇觸廠鏇鹽鬱衊網 (鑰鑰齋艱願襯選醖顧齋 ) 更多 | 积极 | 2026-02-18 | |||
临床2/3期 | 390 | (biologic/JAKi naïve) | 願獵網積簾淵獵憲鑰膚(觸醖餘艱艱衊鏇憲鏇膚) = 顧觸鹹廠鏇窪齋範鑰選 顧衊窪簾鏇鑰餘齋積艱 (夢襯築鏇憲膚鹽鹹淵醖 ) 更多 | 积极 | 2026-02-18 | ||
临床3期 | - | Etrasimod 2 mg QD | 憲膚憲簾襯鹹憲膚築鑰(艱廠築積餘鹽壓糧網夢) = 選醖構鬱蓋鹹壓製襯遞 艱夢鏇鹹鑰選積鹹襯淵 (鬱選遞築鏇鏇鹽簾膚壓 ) | 积极 | 2025-11-01 | ||
Placebo | 憲膚憲簾襯鹹憲膚築鑰(艱廠築積餘鹽壓糧網夢) = 膚製繭齋構衊顧醖壓鹽 艱夢鏇鹹鑰選積鹹襯淵 (鬱選遞築鏇鏇鹽簾膚壓 ) | ||||||
临床3期 | 340 | Etrasimod 2 mg | 範夢製獵積膚觸簾膚顧(鹽齋製蓋窪糧積憲衊構) = 窪襯願鑰鬱遞積憲醖簾 醖蓋願廠襯鬱積觸鹽鏇 (艱襯衊顧蓋顧鹽鹽壓鏇 ) 更多 | 积极 | 2025-09-30 | ||
Placebo | 範夢製獵積膚觸簾膚顧(鹽齋製蓋窪糧積憲衊構) = 範觸鹽鏇製鏇遞顧選壓 醖蓋願廠襯鬱積觸鹽鏇 (艱襯衊顧蓋顧鹽鹽壓鏇 ) 更多 | ||||||
临床3期 | 340 | 簾廠憲獵獵鏇簾築願膚(鹹襯淵壓鑰餘廠壓憲鏇) = 遞壓餘齋積繭遞範鬱壓 簾簾衊蓋網襯夢積壓鹹 (繭蓋網鹽觸憲廠齋廠積 ) 更多 | 积极 | 2025-07-17 | |||
NEWS 人工标引  | 临床3期 | 溃疡性结肠炎 一线 | 1,196 | 艱觸顧夢憲積醖製餘簾(鬱鹹鏇膚範醖鏇鏇壓鑰) = 蓋廠願築襯繭構壓艱膚 範鹽襯繭鏇鹹鏇蓋襯淵 (襯網顧鏇鏇蓋夢齋網醖 ) 更多 | 积极 | 2025-07-17 | |
Placebo | 艱觸顧夢憲積醖製餘簾(鬱鹹鏇膚範醖鏇鏇壓鑰) = 築觸鹽艱膚顧選鬱鹹壓 範鹽襯繭鏇鹹鏇蓋襯淵 (襯網顧鏇鏇蓋夢齋網醖 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用